News

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.

Results showed comparable clinically meaningful improvements in health-related quality of life among patients treated with the adalimumab reference product and biosimilar adalimumab-adbm.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.

Study finds elevated HAMD-17 scores in PBC patients predict cirrhosis risk, with depressive symptoms linked to higher liver enzyme levels and worse UDCA response.

In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.

In this episode, hosts take a break from the ADCES meeting to discuss the latest news from Medtronic related to their Simplera CGM and their partnership with Abbott.

A new study using FDA's Sentinel System found no significant association between recombinant zoster vaccine and incident gout in adults aged 50+.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

These data suggest benefits to pregnant mothers with this condition following early biologic intervention, with treatment leading to rapid refractory pustular psoriasis remission.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.